Skip to main
  1. Stocks
  2. Exelixis
  3. Forecast
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 17%
Buy 8%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis is fundamentally supported by Cabometyx’s durable commercial franchise, which produced $604.9M in sales out of $658.7M in 3Q26 revenue, while diluted net earnings of $0.85 per share and ~$1.4B in cash, cash equivalents, and marketable securities show strong current profitability and balance-sheet flexibility. Its longer-term outlook is strengthened by a pipeline led by zanzalintinib, which is in six pivotal programs and could diversify growth beyond Cabometyx as generics are expected to begin eroding the franchise in 2031, with management also reinvesting cash into broader precision-oncology opportunities. Near-term catalysts such as the 1Q27 STELLAR-304 readout and potential March 3, 2027 FDA approval for zanzalintinib plus atezolizumab, combined with the company’s ability to fund development without additional equity financing, underpin the positive fundamental view.

Bears say

Exelixis is viewed negatively because Cabometyx, the company’s core profit driver, faces an approaching patent cliff and likely market-share erosion in RCC as new regimens and 505(b)(2) copycats intensify pricing pressure. At the same time, management’s next growth engine, zanzalintinib, is still too early to offset Cabometyx’s slowing organic volume growth, and its value is highly concentrated at about two-thirds of operating value, making any regulatory or clinical disappointment especially damaging. If Cabometyx also fails to gain meaningful traction in NETs or HCC, the company’s revenue base and earnings power could compress sharply, leaving the stock vulnerable to volatility and downside.

Exelixis (EXEL) has been analyzed by 12 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 8% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Exelixis (EXEL) Analyst Forecast & Price Prediction

Get the latest Exelixis (EXEL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Exelixis (EXEL)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Hold based on their latest research and market trends.

According to 12 analysts, Exelixis (EXEL) has a Hold consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $59.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $59.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Exelixis (EXEL) Analyst Forecast & Price Prediction

Get the latest Exelixis (EXEL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Exelixis (EXEL)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover EXEL stock data and trends